Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avanir Pharmaceuticals
With
Syneos Health
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to McDonald criteria, 2001)
The patient has a clinical history and clinical relevant symptoms of Pseudobulbar Affect (PBA)
CNS-LS score at baseline is 13 or greater
You may not be if
Patients with myasthenia gravis
Any personal history of complete heart block, QTc prolongation, or torsades de pointes
Any family history of congenital QT interval prolongation syndrome
Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.)
Clareo Health | Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
